Von Willebrand Disease Treatment Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)
Market Report I 2023-01-23 I 111 Pages I Mordor Intelligence
The Von Willebrand disease treatment market is expected to register a CAGR of 6.5% during the forecast period (2022-2027).
The COVID-19 pandemic has significantly impacted the Von Willebrand disease treatment market. For instance, as per a September 2021 published article titled, "Role of von Willebrand Factor in COVID-19 Associated Coagulopathy," patients with COVID-19 have significantly elevated levels of the Von Willebrand factor (vWF) antigen, contributing to an increased risk of thrombosis seen in COVID-19 associated coagulopathy (CAC). As per the same source, the high levels of both vWF antigen and activity have been clinically correlated with worse outcomes. Thus, the demand for Von Willebrand disease treatment is anticipated to rise, thereby contributing to market growth. On the other hand, the lack of awareness and the high cost of the treatment are the factors hindering the market growth.
The major factors fueling the market growth are the increase in patient assistance programs and the growing healthcare expenditure.
In July 2021, the PAN Foundation opened a new patient assistance program for people living with the Von Willebrand disease. The patients who qualify for this program receive USD 10,200 per year in financial assistance to pay for the deductibles, co-pays, and coinsurance costs associated with the treatment for the disease. Another initiative is the Octapharma Co-Pay Assistance Program. This program is available through Factor My Way and provides eligible patients with significant savings on some of the costs associated with their treatment. Such programs propel the demand for the treatment of the Von Willebrand disease, thereby contributing to the growth of the market.
Thus, owing to the abovementioned factors, the market is expected to show growth over the forecast period. However, lack of awareness and high cost of treatment may hamper the growth of the market.
Von Willebrand Disease Treatment Market Trends
Replacement Therapy Segment Expected to Register Significant Growth Over the Forecast Period
The replacement therapy segment is anticipated to witness significant growth. Replacement therapy is referred to as the therapy involving the supply of a substance (such as a hormone or nutrient) lacking in or lost from the body. The major factors fueling the segment's growth are the number of people with Von Willebrand disease and the increasing number of product approvals.
As per the Annual Global Survey by the World Hemophilia Federation, in 2020, the total number of people identified with the Von Willebrand disease globally was 84,197. In addition, several market players are engaged in obtaining approvals for replacement therapies for the treatment of the Von Willebrand disease. For instance, in June 2021, Takeda Pharmaceutical Company Limited reported that the United States Food and Drug Administration (FDA) had accepted the supplemental Biologics License Application (sBLA) for VONVENDI [von Willebrand factor (Recombinant)] for review. This is meant for prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults (aged 18 years and older) with von Willebrand disease.
Thus, due to the above-mentioned factors, the segment is expected to witness significant growth over the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period
Within North America, the United States holds the major share of the market. The major factors contributing to the market growth in the United States are the rising incidence of Von Willebrand disease, the growing number of strategic initiatives, and the growing number of patient assistance programs.
As per the Annual Global Survey by the World Hemophilia Federation, in 2020, the total number of people identified with Von Willebrand disorder in the United States was 8,919. Also, as per an April 2021 update by the Centers for Disease Control and Prevention (CDC), Von Willebrand disease is the most common bleeding disorder in the country. 3.2 million people (or around one person in every 100 people) in the United States have the disease. Therefore, there is a significant demand for the treatment of this disease in the United States, which contributes to the market growth.
There are several initiatives to raise awareness of the Von Willebrand disease. For instance, in August 2020, the National Hemophilia Foundation and Takeda partnered with Alex Borstein to raise awareness regarding the Von Willebrand disease.
Thus, due to the above-mentioned factors, the region is expected to witness significant growth during the forecast period.
Von Willebrand Disease Treatment Market Competitor Analysis
The Von Willebrand disease treatment market is competitive, with the presence of many global players. The most prominent players in the market are Bayer AG, CSL Behring, Ferring Pharmaceuticals, Grifols, Octapharma AG, Pfizer, Sanofi, Sun Pharmaceutical, and Takeda.
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Patient Assistance Programs
4.2.2 Growing Healthcare Expenditure
4.3 Market Restraints
4.3.1 Lack of Awareness
4.3.2 High Cost of Treatment
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Disease Type
5.1.1 Type 1
5.1.2 Type 2
5.1.3 Type 3
5.1.4 Acquired VWD
5.2 By Treatment Type
5.2.1 Desmopressin
5.2.2 Replacement Therapies
5.2.3 Clot-stabilizing Medications
5.2.4 Other Treatment Types
5.3 By Route of Administration
5.3.1 Oral
5.3.2 Injection
5.3.3 Other Routes of Administration
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 CSL Behring
6.1.2 Ferring Pharmaceuticals
6.1.3 Grifols SA
6.1.4 Octapharma AG
6.1.5 Pfizer Inc.
6.1.6 Sanofi SA
6.1.7 Takeda Pharmaceutical Company Ltd
6.1.8 Bio Products Laboratory Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.